49 results
8-K
EX-10.1
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
of certain workforce reductions); the Employee Retirement Income Security Act of 1974 (which, among other things, protects employee benefits); the Fair Labor
8-K
EX-99.1
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
associated with reductions in workforce, including reduced morale and attrition of additional employees necessary for the strategic reprioritization
8-K
EX-99.1
SLRX
Salarius Pharmaceuticals Inc
10 Aug 23
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
4:14pm
of strategic alternatives and in order to extend its resources, Salarius is implementing a cost-savings plan that includes a reduction in workforce
424B5
gi38uzvbl
25 Apr 22
Prospectus supplement for primary offering
5:40pm
424B5
9egy 6oqvq
2 Jul 21
Prospectus supplement for primary offering
5:06pm
424B5
kix6q4vh
1 Jul 21
Prospectus supplement for primary offering
5:13pm
424B5
mowgeubv7qpc5
5 Mar 21
Prospectus supplement for primary offering
5:27pm
424B5
6hi7ifr0ilo5xv66q m8
3 Mar 21
Prospectus supplement for primary offering
4:46pm
424B5
t0ydmg002c20i
5 Feb 21
Prospectus supplement for primary offering
5:15pm
424B5
ulieioxtp8dd258n
31 Jul 20
Prospectus supplement for primary offering
12:00am
424B5
0gr4 6mbgl6e9te3hj7t
29 Jul 20
Prospectus supplement for primary offering
5:27pm